EPICARE-DUO LASER SYSTEM

K091625 · Light Age, Inc. · GEX · Nov 3, 2009 · General, Plastic Surgery

Device Facts

• Record ID: K091625
• Device Name: EPICARE-DUO LASER SYSTEM
• Applicant: Light Age, Inc.
• Product Code: GEX · General, Plastic Surgery
• Decision Date: Nov 3, 2009
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4810
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Light Age, Inc. EpiCare-DUO™ Laser System is intended for use in general and plastic surgery, dermatology, and podiatry for the treatment of vascular lesions, benign pigmented lesions, for removal of dark tattoo inks and reduction of hypertrophic and keloid scars and for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime on all skin types (Fitzpatrick I-VI including tanned skin.) No new indications were sought in this 510(K) and no clinical data is presented.

Device Story

Class IV laser surgical instrument; emits pulsed energy at 755 nm (alexandrite) and 1064 nm (Nd:YAG) wavelengths. System comprises laser source, microprocessor-based control unit, laptop user interface, flexible optical fiber with handpiece, and foot pedal switch. Operated by clinicians in medical/cosmetic settings. Laser energy delivered to target area via handpiece; visible aiming beam guides application. Output used for photocoagulation, hemostasis, and selective targeting of melanin or vascular structures. Clinical benefit includes lesion reduction, hair removal, and scar management. Device design is identical to predicate EpiCare™ in 755 nm mode; 1064 nm mode adds Nd:YAG capability.

Clinical Evidence

No clinical data presented. Substantial equivalence is based on design analysis and performance characteristics compared to predicate devices.

Technological Characteristics

Class IV laser; alexandrite (755 nm) and Nd:YAG (1064 nm) crystal rods. Microprocessor-controlled. Includes laptop UI, optical fiber delivery, and foot pedal. Complies with 21 CFR 1040.10/11, IEC 60601-1, IEC 60601-1-1, IEC 60601-1-2, and IEC 60601-1-22.

Indications for Use

Indicated for patients of all skin types (Fitzpatrick I-VI, including tanned skin) requiring treatment for vascular lesions, benign pigmented lesions, wrinkles, hypertrophic/keloid scars, pseudofolliculitis barbae, or removal of unwanted hair and dark tattoo inks. Used in general/plastic surgery, dermatology, and podiatry.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

• Light Age, Inc. EpiCare™ Alexandrite Laser System (K032991)
• Cynosure Apogee Elite (K034030)
• Candela Corp GentleLase Family of Lasers (K063074)

Submission Summary (Full Text)

{0}------------------------------------------------

# EpiCare-DUO™ Laser System

# 510(k) Summarv EpiCare-DUO™ Laser System

June 1, 2009

Submittal Information Post Approval Contact: Dr. Donald F. Heller Chief Executive Officer Betsy Reddington Director of Regulatory Affairs Light Age, Inc. 500 Apgar Drive Somerset, NJ 08873 Tel: [phone] Fax: [phone]

Device Name and Classification

| 510(k) Number: | K091625 |
|------------------------|-------------------------------------|
| Proprietary Name: | Light Age EpiCare-DUO™ Laser System |
| Common Name: | Alexandrite and Nd:YAG Laser System |
| Classification Name: | Class IV Laser Surgical Instrument |
| Classification Panel : | General & Plastic Surgery Devices |
| C.F.R. Section | 878.4810 |
| Device Class: | II |
| Product Code: | GEX |

#### Predicate Devices:

- Light Age, Inc. EpiCare™ Alexandrite Laser System [K032991], t
- Cynosure Apogee Elite (K034030], .
- Candela Corp GentleLase Family of Lasers [K063074] .

# Device Description:

The Light Age EpiCare-DUO™ Laser is a Class IV Laser Surgical Instrument for use in General medical/cosmetic procedures, General and Plastic surgery, Podiatry, and Dermatology. Using alexandrite and neodymium (Nd) YAG crystal rods, pused energy is emitted at 755 and 1064 nanometers in the near infrared portion of the spectrum under the guidance of a visible aiming beam. The device consists of the fploving components and accessories:

- 1. Laser Source and Onboard Microprocessor Based Control unit
- 2. Laptop User Interface

NOV - 8 2009

{1}------------------------------------------------

- 3. Flexible Optical Fiber and handpiece delivers energy from the laser to the target area via optical fiber with handpiece, which produces a circular bearn on the skin.
- 4. Foot Pedal Switch activates delivery when lasers are enabled.

## Intended Use:

The Light Age EpiCare-Duo™ Laser System delivers variable pulse laser light in the near infrared portion of the spectrum during procedures. The Light Age, Inc. EpiCare-DUO™ Laser System is intended for use in general and plastic surgery, derrepodry. and podiatry for the treatment of vascular lesions, benign pigmented lesions, writkles, for removal of dark tattoo inks and reduction of hypertrophic and keloid stars and for hair removal, and stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime on all skin types (Fitzpatrick I-VI) including tanned skiro. No new indications were sought in this 510(K) and no clinical data is presented.

## Performance Standards

- The EpiCare-DUO™ complies with applicable performance standards for light . emitting products as outlined in 21 CFR1040.10 and 21 CFR1040.11.
- The device also conforms to the voluntary electrical equipment standards: . IEC 60601-1, IEC 60601-1-1, IEC 60601-1-2, and IEC 60601-1-22.

#### Substantial Equivalence:

The reason for this 510(k) is a design change. Light Age, inc. is adding a (Nd:YAG) capability to our EpiCare™ alexandrite laser system that has been cleared and in use since 2001.

The candidate device is identical in design and operation to the previously cleared EpiCare™ laser system when operated in the 755 nm wavelength mode. In the 1064 nm mode the candidate device is substantially equivalent in operation and efficacy to the other predicate devices,

#### Safety and Effectiveness:

The Light Age, Inc. EpiCare-DUO™ Laser System should not raise any concerns regarding its overall safety and effectiveness. In the nearly one decade of use with over 1 million treatments performed the EpiCare™ product family has been proven to be clinically safe with no reports of significant patient or operator injury.

The Light Age, Inc. EpiCare-DUO™ is designed in accordance with both mandatory and voluntary standards ensuring it is both safe and effective for cosmetic/medical procedures indicated above. No new clinical indications are to be providedly the introduction of this device as compared to the predicate devices, identified above, which have previously demonstrated clinical effectiveness..

{2}------------------------------------------------

## Indications for Use:

The Light Age, Inc. EpiCare-DUO™ Laser System is intended for use in general and plastic surgery, dermatology, and podiatry for the treatment of gascular lesions, benign pigmented lesions, for removal of dark tattoo inks and reduction of hypertrophic and keloid scars, hair removal, and for stable long-teenon, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime on all skin types (Fitzpatrick I-VI including tanned skin.) No new indications were sought in this 510(K) and no clinical data is presented.

Light Age, Inc. Is providing more specialized indications, which are a subset of the previously cleared indications. From both a design and clinical perspective, the predicate and candidate laser devices, are of the same technology and have the same intended use. Based upon an analysis of the overall performance characteristics for the devices. Light Age, Inc. believes that no significant differences exist.

755nm - Specifically the 755 nm mode is indicated

- Hair removal, and stable long-term or permanent hair reduction through . selective targeting of melanin in hair follicles on all skin types (Fitzpatrick I-VI) including tanned skin. Permanent hair reduction is defined as longterm stable reduction in the number of hair regrowth after a treatment regime. The number of hairs re-growing must be stable over a time greater than the duration of the complete growth cycle of hair follicies, which varies from 4-12 months according to body location. Permanent hair reduction does not necessarily imply the elimination of all hairs in the treated area.
- Treatment of vascular lesions 다
- Treatment of benign pigmented lesions. な
- � Treatment of wrinkles.

#### 1064nm -

- Removal of unwanted hair, for stable long term or permanent hair . reduction on all skin types Fitzpatrick I-VI including tanned skin.
- Photocoagulation and hemostasis of pigmented and vascular lesions, such . as but not limited to port wine stains, hemoangioma, warts, telangiectasia, rosacea, venus lake, leg veins, and spider veins and poikiloderma of civatte. Coagulation and hemostasis of soft tissue.
- Benign cutaneous lesions such as warts, scars striac and psoriasis. �
- Benign pigmented lesions such as, but not limited to, lentigos (age spots), す solar lentigos (sun spots), café au lait macules, seborrheio keratoses,

{3}------------------------------------------------

nevi, chloasma, verrucae, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plagues.

- Pigmented lesion size reduction in patients with lesions who would � potentially benefit from aggressive treatment, and for patients with ' round that have not responded to other laser treatments.
- Reduction of red pigmentation in hypertrophic and keloid scars where . vascularity is an integral part of the scar.
- Treatment of pseudofolliculitis barbae (PFB). �
- Treatment of wrinkles including but not limited periocular wrinkles and � perioral wrinkles,

No new indications were sought in this premarket notification and no clinical data is presented.

Light Age, Inc. is providing more specialized indications which are a subset of the previously cleared indications. From both a design and clinical perspective the predicate and candidate laser devices, are of the same technology and have the same intended use. Based upon an analysis of the overall performance characteristics for the devices, Light Age, Inc. believes that no significant differences exist.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular, with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. In the center of the seal is an abstract image of an eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-O66-0609 Silver Spring, MD 20993-0002

Light Age, Inc. % Ms. Elizabeth Reddington Director of Regulatory Affairs 500 Apgar Drive Somerset, New Jersey 08873

NOV - 3 2009

Re: K091625

Trade/Device Name: Light Age, EpiCare-DuoTM Laser System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: Class II Product Code: GEX Dated: October 16, 2009 Received: October 19, 2009

Dear Ms. Reddington:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{5}------------------------------------------------

Page 2 - Ms. Elizabeth Reddington

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{6}------------------------------------------------

-- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EpiCare-DUO™ Laser System

510(K) 091625

# INDICATIONS FOR USE STATEMENT

Device Name: Light Age, Inc EpiCare-DUOTM Laser System

The Light Age, Inc. EpiCare-DUO™ Laser System is intended for use in general and plastic surgery, dermatology, and podiatry for the treatment of vascular lesions, benign pigmented lesions, for removal of dark tattoo inks and reduction of hypertrophic and keloid scars and for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime on all skin types (Fitzpatrick I-VI including tanned skin.) No new indications were sought in this 510(K) and no clinical data is presented.

Light Age, Inc. is providing more specialized indications which are a subset of the previously cleared indications. From both a design and clinical perspective, the predicate and candidate laser devices, are of the same technology and have the same intended use. Based upon an analysis of the overall performance characteristics for the devices, Light Age, Inc. believes that no significant differences exist.

755nm - Specifically the 755 nm mode is indicated

- Hair removal, and stable long-term or permanent hair reduction through selective . targeting of melanin in hair follicles on all skin types (Fitzpatrick I-VI) including tanned skin. Permanent hair reduction is defined as long-term stable reduction in the number of hair regrowth after a treatment regime. The number of hairs regrowing must be stable over a time greater than the duration of the complete growth cycle of hair follicles, which varies from 4-12 months according to body location. Permanent hair reduction does not necessarily imply the elimination of all hairs in the treated area.
- Treatment of vascular lesions .

eil R.P.Ogle for mxm
(Division Sign-Off)

- Treatment of benign pigmented lesions. .
- . Treatment of wrinkles.

510(k) Number K091625

Division of Surgical, Orthopedie,

and Restorative Devices

1064nm -

- Removal of unwanted hair, for stable long term or permanent hair reduction on all . skin types Fitzpatrick 1-VI including tanned skin.
- Photocoagulation and hemostasis of pigmented and vascular lesions such as but .

Page 1 of 2

{7}------------------------------------------------

## EpiCare-DUO™ Laser System

not limited to port wine stains, hemoangioma, warts, telangiectasia, rosacea, venus lake, leg veins, and spider veins and poikiloderma of civatte. Coagulation and hemostasis of soft tissue.

- . Benign cutaneous lesions such as warts, scars striac and psoriasis.
- . Benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), café au lait macules, seborrheio keratoses, nevi, chloasma, verrucae, skin tags, keratoses, tattoos (significant reduction in the intensity of black and/or blue-black tattoos) and plaques.
- . Pigmented lesion size reduction in patients with lesions who would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments.
- Reduction of red pigmentation in hypertrophic and keloid scars where vascularity . is an integral part of the scar.
- Treatment of pseudofolliculitis barbae (PFB). .
- . Treatment of wrinkles including but not limited periocular wrinkles and perioral wrinkles.

(Please Do Not Write Below This Line - Continue on Another Page If Needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X (Per 21 CFR 801.109) OR

Over the Counter Use

Neil R. Olson for main

(Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number K091625

(Optional Format 1-2-06)

Page 2 of 2